The shadow of generic competition has long loomed around copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the future of related drug portfolios. While first times saw significant returns, the intellectual property expiration has created the path for discounted copies, possibly lowering profitability and presenting a genuine